Download
s00262-020-02734-1.pdf 6,33MB
WeightNameValue
1000 Titel
  • Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma
1000 Autor/in
  1. Leuchte, Katharina |
  2. Staib, Elena |
  3. Thelen, Martin |
  4. Gödel, Philipp |
  5. Lechner, Axel |
  6. Zentis, Peter |
  7. Garcia-Marquez, Maria |
  8. Waldschmidt, Dirk |
  9. Datta, Rabi Raj |
  10. Wahba, Roger |
  11. Wybranski, Christian |
  12. Zander, Thomas |
  13. Quaas, Alexander |
  14. Drebber, Uta |
  15. Stippel, Dirk Ludger |
  16. Bruns, Christiane |
  17. von Bergwelt-Baildon, Michael |
  18. Wennhold, Kerstin |
  19. Schlößer, Hans Anton |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-10-02
1000 Erschienen in
1000 Quellenangabe
  • 70(4):893-907
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00262-020-02734-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979675/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Thermal ablative therapies are standard treatments for localized hepatocellular carcinoma (HCC). In addition to local tumor destruction, ablation leads to abscopal effects in distant lesions most likely mediated by an anti-tumor immune response. Although microwave ablation (MWA) is increasingly substituting other ablative techniques, its systemic immunostimulatory effects are poorly studied. We analyzed tumor-specific immune responses in peripheral blood of HCC patients after thermal ablation with regard to T cell responses and disease outcome. While comprehensive flow cytometric analyses in sequential samples of a prospective patient cohort (n = 23) demonstrated only moderate effects of MWA on circulating immune cell subsets, fluorospot analyses of specific T cell responses against seven tumor-associated antigens (TTAs) revealed de-novo or enhanced tumor-specific immune responses in 30% of patients. This anti-tumor immune response was related to tumor control as Interferon-y and Interleukin-5 T cell responses against TAAs were more frequent in patients with a long-time remission (> 1 year) after MWA (7/16) compared to patients suffering from an early relapse (0/13 patients) and presence of tumor-specific T cell response (IFN-y and/or IL-5) was associated to longer progression-free survival (27.5 vs. 10.0 months). Digital image analysis of immunohistochemically stained archival HCC samples (n = 18) of patients receiving combined MWA and resection revealed a superior disease-free survival of patients with high T cell abundance at the time of thermal ablation (37.4 vs. 13.1 months). Our data demonstrates remarkable immune-related effects of MWA in HCC patients and provides additional evidence for a combination of local ablation and immunotherapy in this challenging disease.
1000 Sacherschließung
lokal Liver Neoplasms/surgery [MeSH]
lokal Carcinoma, Hepatocellular/immunology [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Antigens
lokal Liver Neoplasms/immunology [MeSH]
lokal Original Article
lokal Liver Neoplasms/pathology [MeSH]
lokal Carcinoma, Hepatocellular/surgery [MeSH]
lokal Male [MeSH]
lokal Immunogenic cell death
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Carcinoma, Hepatocellular/pathology [MeSH]
lokal Catheter Ablation/methods [MeSH]
lokal Middle Aged [MeSH]
lokal Survival Rate [MeSH]
lokal Microwaves/therapeutic use [MeSH]
lokal Immunity/immunology [MeSH]
lokal Immunotherapy
lokal Prognosis [MeSH]
lokal Abscopal effect
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-1094-0840|https://frl.publisso.de/adhoc/uri/U3RhaWIsIEVsZW5h|https://frl.publisso.de/adhoc/uri/VGhlbGVuLCBNYXJ0aW4=|https://frl.publisso.de/adhoc/uri/R8O2ZGVsLCBQaGlsaXBw|https://frl.publisso.de/adhoc/uri/TGVjaG5lciwgQXhlbA==|https://frl.publisso.de/adhoc/uri/WmVudGlzLCBQZXRlcg==|https://frl.publisso.de/adhoc/uri/R2FyY2lhLU1hcnF1ZXosIE1hcmlh|https://frl.publisso.de/adhoc/uri/V2FsZHNjaG1pZHQsIERpcms=|https://frl.publisso.de/adhoc/uri/RGF0dGEsIFJhYmkgUmFq|https://frl.publisso.de/adhoc/uri/V2FoYmEsIFJvZ2Vy|https://frl.publisso.de/adhoc/uri/V3licmFuc2tpLCBDaHJpc3RpYW4=|https://frl.publisso.de/adhoc/uri/WmFuZGVyLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/UXVhYXMsIEFsZXhhbmRlcg==|https://frl.publisso.de/adhoc/uri/RHJlYmJlciwgVXRh|https://frl.publisso.de/adhoc/uri/U3RpcHBlbCwgRGlyayBMdWRnZXI=|https://frl.publisso.de/adhoc/uri/QnJ1bnMsIENocmlzdGlhbmU=|https://frl.publisso.de/adhoc/uri/dm9uIEJlcmd3ZWx0LUJhaWxkb24sIE1pY2hhZWw=|https://frl.publisso.de/adhoc/uri/V2VubmhvbGQsIEtlcnN0aW4=|https://frl.publisso.de/adhoc/uri/U2NobMO2w59lciwgSGFucyBBbnRvbg==
1000 Hinweis
  • DeepGreen-ID: 17af1e37c42d45b0abf2bc843f2b777f ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6470058.rdf
1000 Erstellt am 2023-11-18T03:34:58.693+0100
1000 Erstellt von 322
1000 beschreibt frl:6470058
1000 Zuletzt bearbeitet 2023-12-01T11:04:25.536+0100
1000 Objekt bearb. Fri Dec 01 11:04:25 CET 2023
1000 Vgl. frl:6470058
1000 Oai Id
  1. oai:frl.publisso.de:frl:6470058 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source